ArticleHepatology international2008
Pathogenetic background for treatment of ascites and hepatorenal syndrome.
Article in Hepatology international, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Neutrophil to Lymphocyte Ratio and Spontaneous Bacterial Peritonitis among Cirrhotic Patients: A Systematic Review and Meta-analysis.Canadian journal of gastroenterology & hepatology · 2022Pooled it
- Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.World journal of gastroenterology · 2017Trial
- Liver and systemic hemodynamics in cirrhotic children.World journal of hepatology · 2025Review
- Continuous Non-Invasive Hemodynamic Monitoring in Cirrhotic Patients-Friend or Foe?Medicina (Kaunas, Lithuania) · 2025Article
- Role of albumin infusion in cirrhosis-associated complications.Clinical and experimental medicine · 2024Review
- Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure.Frontiers in medicine · 2023Review
- COVID-19 and hepatorenal syndrome.World journal of gastroenterology · 2022Review
- Human Amnion-Derived Mesenchymal Stromal Cells in Cirrhotic Patients with Refractory Ascites: A Possible Anti-Inflammatory Therapy for Preventing Spontaneous Bacterial Peritonitis.Stem cell reviews and reports · 2021Article
- Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.Nature reviews. Cardiology · 2021Review
- [Research advances in pathophysiology and diagnosis and treatment of hepatorenal syndrome].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017Article
- Role of albumin in cirrhosis: from a hospitalist's perspective.Journal of community hospital internal medicine perspectives · 2017Review
- Hepatorenal Syndrome: A Review of Pathophysiology and Current Treatment Options.Seminars in interventional radiology · 2015Review
- Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction.Hepatology international · 2015Review
- Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate.Hepatology international · 2011Article
- The interstitial lymphatic peritoneal mesothelium axis in portal hypertensive ascites: when in danger, go back to the sea.International journal of inflammation · 2010Article
- Renal dysfunction in patients with chronic liver disease.Electrolyte & blood pressure : E & BP · 2009Article
- Cardiovascular changes in cirrhosis: pathogenesis and clinical implications.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ascites and hepatorenal syndrome (HRS) are the major and challenging complications of cirrhosis and portal hypertension that significantly affect the course of the disease. Liver insufficiency, portal hypertension, arterial vasodilatation, and systemic cardiovascular dysfunction are major pathophysiological hallmarks. Modern treatment of ascites is based on this recognition and includes modest salt restriction and stepwise diuretic therapy with spironolactone and loop diuretics. Tense and refractory ascites should be treated with a large volume paracentesis, followed by volume expansion or transjugular intrahepatic portosystemic shunt. New treatment strategies include the use of vasopressin V(2)-receptor antagonists and vasoconstrictors. The HRS denotes a functional and reversible impairment of renal function in patients with severe cirrhosis with a poor prognosis. Attempts of treatment should seek to improve liver function, ameliorate arterial hypotension and central hypovolemia, and reduce renal vasoconstriction. Ample treatment of ascites and HRS is important to improve the quality of life and prevent further complications, but since treatment of fluid retention does not significantly improve survival, these patients should always be considered for liver transplantation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.